PRICE T ROWE ASSOCIATES INC /MD/ - RIGEL PHARMACEUTICALS INC ownership

RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 125 filers reported holding RIGEL PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.0%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of RIGEL PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$109
-14.8%
100,246
+1.4%
0.00%
Q2 2023$128
-14.1%
98,874
-12.4%
0.00%
Q1 2023$149
-8.6%
112,821
+3.8%
0.00%
Q4 2022$163
-99.9%
108,7130.0%0.00%
Q3 2022$129,000
-32.1%
108,713
-35.4%
0.00%
Q2 2022$190,000
-23.4%
168,302
+102.5%
0.00%
Q1 2022$248,000
+72.2%
83,102
+52.6%
0.00%
Q4 2021$144,000
-31.4%
54,456
-6.0%
0.00%
Q3 2021$210,000
-15.0%
57,956
+2.0%
0.00%
Q2 2021$247,000
+64.7%
56,847
+29.3%
0.00%
Q1 2021$150,000
+265.9%
43,952
+278.5%
0.00%
Q4 2020$41,000
+36.7%
11,612
-7.2%
0.00%
Q3 2020$30,000
+30.4%
12,5120.0%0.00%
Q2 2020$23,000
-99.6%
12,512
-99.7%
0.00%
-100.0%
Q1 2020$6,146,000
-24.9%
3,939,869
+3.0%
0.00%0.0%
Q4 2019$8,189,000
+14.8%
3,826,406
+0.3%
0.00%0.0%
Q3 2019$7,133,000
-46.4%
3,814,699
-25.1%
0.00%
-50.0%
Q2 2019$13,301,000
+1.6%
5,096,227
+0.0%
0.00%0.0%
Q1 2019$13,096,000
+24.8%
5,095,827
+11.7%
0.00%0.0%
Q4 2018$10,494,000
-28.1%
4,562,621
+0.3%
0.00%0.0%
Q3 2018$14,596,000
+45.7%
4,547,115
+28.4%
0.00%0.0%
Q2 2018$10,021,000
+5.4%
3,540,851
+31.8%
0.00%0.0%
Q1 2018$9,508,000
-8.7%
2,685,759
+0.1%
0.00%0.0%
Q4 2017$10,414,000
+47.4%
2,683,953
-3.5%
0.00%
+100.0%
Q3 2017$7,064,000
+9.6%
2,781,153
+17.8%
0.00%0.0%
Q2 2017$6,444,000
-29.3%
2,360,603
-14.3%
0.00%
-50.0%
Q1 2017$9,115,000
+123.5%
2,753,833
+60.7%
0.00%
+100.0%
Q4 2016$4,079,000
+14.1%
1,714,030
+75.9%
0.00%0.0%
Q3 2016$3,576,000
+662.5%
974,365
+363.2%
0.00%
Q2 2016$469,000
+7.1%
210,3600.0%0.00%
Q1 2016$438,000
-31.7%
210,360
-0.6%
0.00%
Q4 2015$641,000
+16.8%
211,650
-4.9%
0.00%
Q3 2015$549,000
-23.0%
222,450
+0.1%
0.00%
Q2 2015$713,000
-10.1%
222,2000.0%0.00%
Q1 2015$793,000
+60.9%
222,200
+2.3%
0.00%
Q4 2014$493,000
+17.1%
217,2000.0%0.00%
Q3 2014$421,000
-46.6%
217,2000.0%0.00%
Q2 2014$788,000
+28.5%
217,200
+37.5%
0.00%
Q1 2014$613,000
-96.3%
157,920
-96.6%
0.00%
-100.0%
Q3 2013$16,510,000
-50.2%
4,611,800
-53.6%
0.00%0.0%
Q2 2013$33,164,0009,929,2000.00%
Other shareholders
RIGEL PHARMACEUTICALS INC shareholders Q1 2023
NameSharesValueWeighting ↓
DAFNA Capital Management LLC 1,847,087$4,119,0003.26%
Sio Capital Management, LLC 1,333,696$2,974,0001.52%
Boxer Capital, LLC 700,000$1,561,0001.38%
Palo Alto Investors LP 5,386,534$12,012,0000.91%
ACUTA CAPITAL PARTNERS, LLC 747,748$1,667,0000.80%
SENZAR ASSET MANAGEMENT, LLC 1,443,003$3,217,897,0000.70%
Ghost Tree Capital, LLC 800,000$1,784,0000.52%
NEA Management Company, LLC 3,243,150$7,232,0000.38%
Rhenman & Partners Asset Management AB 850,000$1,896,0000.34%
Rock Springs Capital Management LP 1,750,000$3,903,0000.29%
View complete list of RIGEL PHARMACEUTICALS INC shareholders